Targeted treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) is a landmark for rational therapy addressing molecular vulnerabilities1. This evidence concerns the gene EGFR and non-small cell lung carcinoma.